will also continue to depend on the willingness of governments worldwide, through their funding agencies, as well as philanthropic foundations and interested corporate sectors, to accelerate a well-focused effort in this direction.

**Acknowledgements**
The authors are grateful to Pinuccia De Tomasi for her expert editorial support and effort in coping with the many versions of this manuscript.

**Funding**
This study was supported by Sigrid Juselius Foundation, Helsinki Finland, and the Foundation for Cardiovascular Research, Helsinki, Finland (H.V.H.); CTMM, the Center for Translational Molecular Medicine (www.ctmm.nl), project COHVAR (grant 01C-203) (A.A.W.). Funding to pay the Open Access publication charges for this article was provided by Medtronic.

**Conflict of interest:** member of the advisory board of Sorin (A.A.W.), Consultancy to Medtronic and St Jude (H.J.J.W.). Retired Medtronic employee, Medtronic shareholder (F.W.L.).

**References**
The list of references is available in the online version of this paper.

---

**CARDIOVASCULAR FLASHLIGHT**

---

**Caval valve implantation for treatment of tricuspid regurgitation: post-mortem evaluation after mid-term follow-up**


1Department of Internal Medicine I (Cardiology and Intensive Care Medicine), University Heart Center Jena, Erlanger Allee 101, 07740 Jena, Germany and 2Department of Cardiothoracic Surgery, University Heart Center Jena, Erlanger Allee 101, 07747 Jena, Germany

* Corresponding author. Tel: +49 36419324518, Fax: +49 36419324102, Email: alexander.lauten@med.uni-jena.de

In a 79-year-old female patient with symptomatic tricuspid regurgitation (TR) ‘first-in-man’ transcatheter valve implantation into the inferior vena cava (IVC) was performed as compassionate treatment. Details of the procedure as well as the clinical course have been reported previously. In brief, a self-expanding pericardial valve was implanted into the IVC in a percutaneous approach through the right femoral vein. Immediate excellent valve function was observed and resulted in haemodynamic and symptomatic improvement. After an uneventful recovery, the patient was discharged from hospital and followed in our outpatient clinic.

After 3 month, she was emergently readmitted due to a large intracranial haemorrhage, which could not be treated and led to death of the patient within 48 h. Autopsy was performed, confirming an unchanged position and excellent function of the valve in the IVC (Panel A). The device was securely anchored with the upper valve segment protruding into the right atrium and leaving the hepatic veins unobstructed (Panel B). The stent struts were largely covered by fibrous tissue, fixing the device and making it unretrievable from the caval vein (Panel C). The leaflets were tender and mobile with sufficient coaptation and without evidence of degeneration, thrombus formation, or other causes of dysfunction.

This post-mortem study of the first human application of caval valve implantation confirms the technical feasibility, safety and device function after mid-term follow-up. This novel approach represents a percutaneous treatment option for a subgroup of patients with severe TR and treatment-refractory symptoms of venous congestion.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2013. For permissions please email: journals.permissions@oup.com